These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32478632)

  • 21. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management.
    Herekar A; Shimoga D; Jehangir A; Shahsavari D; Yan Y; Karunaratne TB; Sharma A
    Clin Exp Gastroenterol; 2023; 16():79-85. PubMed ID: 37309470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review.
    Mosińska P; Salaga M; Fichna J
    Expert Opin Investig Drugs; 2016; 25(3):275-86. PubMed ID: 26765585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
    Rothstein RD; Friedenberg FK
    Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs for Irritable Bowel Syndrome.
    Med Lett Drugs Ther; 2020 Mar; 62(1594):25-32. PubMed ID: 32324172
    [No Abstract]   [Full Text] [Related]  

  • 27. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
    Vazquez-Roque MI; Bouras EP
    Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EFFICACY AND SAFETY OF INTESTINAL SECRETAGOGUES FOR CHRONIC CONSTIPATION: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    Lasa JS; Altamirano MJ; Bracho LF; Paz S; Zubiaurre I
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):2-12. PubMed ID: 30088533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome.
    Mousavi T; Nikfar S; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):583-604. PubMed ID: 32380874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options.
    Wechsler EV; Shah ED
    Drugs; 2021 Nov; 81(17):1953-1968. PubMed ID: 34727333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
    Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
    Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tenapanor administration and the activity of the H
    Johansson S; Rosenbaum DP; Palm J; Stefansson B; Knutsson M; Lisbon EA; Hilgendorf C
    Br J Clin Pharmacol; 2017 Sep; 83(9):2008-2014. PubMed ID: 28432691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?
    Tack J
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):21-6. PubMed ID: 23859757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome.
    Niewinna K; Zielińska A; Fichna J
    Expert Opin Pharmacother; 2020 Jan; 21(1):73-84. PubMed ID: 31724881
    [No Abstract]   [Full Text] [Related]  

  • 35. Review article: current and future treatment approaches for IBS with constipation.
    Liu JJ; Brenner DM
    Aliment Pharmacol Ther; 2021 Dec; 54 Suppl 1():S53-S62. PubMed ID: 34927760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
    King AJ; Siegel M; He Y; Nie B; Wang J; Koo-McCoy S; Minassian NA; Jafri Q; Pan D; Kohler J; Kumaraswamy P; Kozuka K; Lewis JG; Dragoli D; Rosenbaum DP; O'Neill D; Plain A; Greasley PJ; Jönsson-Rylander AC; Karlsson D; Behrendt M; Strömstedt M; Ryden-Bergsten T; Knöpfel T; Pastor Arroyo EM; Hernando N; Marks J; Donowitz M; Wagner CA; Alexander RT; Caldwell JS
    Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
    Lacy BE; Chey WD
    Expert Opin Pharmacother; 2009 Jan; 10(1):143-52. PubMed ID: 19236188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
    Liu R; Staller K
    Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.